Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model

Epilepsy Research

Volumn 86, Issue 2-3, 2009, Pages 163-174

  Wojda, Ewa ^a   Wlaz, Aleksandra ^a   Patsalos, Philip N ^b   Luszczki, Jarogniew J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

6 Hz psychomotor seizure model; Antiepileptic drugs; Drug interactions; Isobolographic analysis; Levetiracetam

Indexed keywords

CLONAZEPAM; ETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; TIAGABINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; EXPERIMENTAL MODEL; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; TASK PERFORMANCE; TEMPORAL LOBE EPILEPSY; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; CLONAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROSHOCK; EPILEPSY; MALE; MICE; PHENOBARBITAL; PIRACETAM; PSYCHOMOTOR PERFORMANCE; VALPROIC ACID;

EID: 70349484436     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.06.003     Document Type: Article

References (59)

1. Barton M.E., Klein B.D., Wolf H.H., and White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47 (2001) 217-227
2. Barton M.E., Peters S.C., and Shannon H.E. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res. 56 (2003) 17-26
3. Berenbaum M.C. What is synergy?. Pharmacol. Rev. 41 (1989) 93-141 (Erratum published in 1989. Pharmacol. Rev. 41, 422)
4. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basle) 3 (1960) 81-84
5. Brown W.C., Schiffman D.O., Swinyard E.A., and Goodman L.S. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J. Pharmacol. Exp. Ther. 107 (1953) 273-283
6. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., and Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
7. Deckers C.L.P., Genton P., Sills G.J., and Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res. 53 (2003) 1-17
8. Donato Di Paola E., Gareri P., Davoli A., Gratteri S., Scicchitano F., Naccari C., and De Sarro G. Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy Res. 75 (2007) 112-121
9. Dudra-Jastrzebska, M., Andres-Mach, M.M., Ratnaraj, N., Patsalos, P.N., Czuczwar, S.J., Luszczki, J.J. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure, doi:10.1016/j.seizure.2009.06.009, in press.
10. Dudra-Jastrzebska M., Andres-Mach M.M., Sielski M., Ratnaraj N., Patsalos P.N., Czuczwar S.J., and Luszczki J.J. Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. Eur. J. Pharmacol. 605 (2009) 87-94
11. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., and Shields W.D. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
12. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22 (1995) 207-213
13. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222 (1992) 193-203 (Erratum published in 1993. Eur. J. Pharmacol. 230, 389)
14. Grabovsky Y., and Tallarida R.J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J. Pharmacol. Exp. Ther. 310 (2004) 981-986
15. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47 (1995) 331-385
16. Jonker D.M., Visser S.A., van der Graaf P.H., Voskuyl R.A., and Danhof M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106 (2005) 1-18
17. Jonker D.M., Voskuyl R.A., and Danhof M. Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat. Epilepsia 45 (2004) 424-435
18. Jonker D.M., Voskuyl R.A., and Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?. Epilepsia 48 (2007) 412-434
19. Kaminski R.M., Matagne A., Patsalos P.N., and Klitgaard H. Benefits of combination therapy in epilepsy: a review of preclinical evidence with levetiracetam. Epilepsia 50 (2009) 387-397
20. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
21. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
22. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-290
23. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
24. Löscher W., and Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232 (1993) 147-158
25. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 8 (1991) 171-189
26. Löscher W., Hönack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284 (1998) 474-479
27. Luszczki J.J. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn-Schmiedebergs Arch. Pharmacol. 375 (2007) 105-114
28. Luszczki J.J. Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. Naunyn-Schmiedebergs Arch. Pharmacol. 378 (2008) 483-492
29. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Wojcik-Cwikla J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur. Neuropsychopharmacol. 15 (2005) 609-616
30. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 47 (2006) 10-20
31. Luszczki J.J., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48 (2007) 806-815
32. Luszczki J.J., Antkiewicz-Michaluk L., and Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 602 (2009) 298-305
33. Luszczki J.J., Borowicz K.K., Swiader M., and Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 489-499
34. Luszczki J.J., Czuczwar M., Kis J., Krysa J., Pasztelan I., Swiader M., and Czuczwar S.J. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 1001-1011
35. Luszczki J.J., and Czuczwar S.J. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics-a comparative study. Epilepsy Res. 56 (2003) 27-42
36. Luszczki J.J., and Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedebergs Arch. Pharmacol. 369 (2004) 434-446
37. Luszczki J.J., and Czuczwar S.J. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 45 (2004) 895-907
38. Luszczki J.J., and Czuczwar S.J. How significant is the difference between drug doses influencing the threshold for electroconvulsions?. Pharmacol. Rep. 57 (2005) 782-786
39. Luszczki J.J., and Czuczwar S.J. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedebergs Arch. Pharmacol. 374 (2006) 51-64
40. Luszczki J.J., and Czuczwar S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 529-538
41. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Epilepsy Behav. 7 (2005) 639-651
42. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol. 373 (2006) 169-181
43. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol. 595 (2008) 13-21
44. Luszczki J.J., Wu J.Z., Raszewski G., and Czuczwar S.J. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch. Pharmacol. 379 (2009) 163-179
45. Margineanu D.G., Matagne A., Kaminski R.M., and Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res. Bull. 77 (2008) 282-285
46. Marrosu F., Bortolato M., Frau R., Orru M., Puligheddu M., Fa M., Muroni A., Tuveri A., and Mereu G. Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy Res. 75 (2007) 224-227
47. Mazarati A.M., Baldwin R., Klitgaard H., Matagne A., and Wasterlain C.G. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 58 (2004) 167-174
48. Meyer O.A., Tilson H.A., Byrd W.C., and Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1 (1979) 233-236
49. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
50. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol. Scand. Suppl. 162 (1995) 31-34
51. Sills G.J., Butler E., Thompson G.G., and Brodie M.J. Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 13 (2004) 287-295
52. Sisodiya S.M., Sander J.W., and Patsalos P.N. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 48 (2002) 217-219
53. Tallarida R.J. Drug Synergism and Dose-Effect Data Analysis (2000), Chapman & Hall/CRC, Boca Raton, USA
54. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319 (2006) 1-7
55. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol. Ther. 113 (2007) 197-209
56. Toman J.E. Neuropharmacologic considerations in psychic seizures. Neurology 1 (1951) 444-460
57. Toman J.E., Everett G.M., and Richards R.K. The search for new drugs against epilepsy. Tex. Rep. Biol. Med. 10 (1952) 96-104
58. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., and Rossier J. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321 (1986) 864-866
59. Vinogradova L.V., and van Rijn C.M. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 49 (2008) 1160-1168